Chinese Herbal Extractions for Relieving Radiation Induced Lung Injury: A Systematic Review and Meta‐Analysis

Deng, Bo; Deng, Chao; Cheng, Zhiqiang

doi:10.1155/2017/2141645

Cited by 6 publications

(4 citation statements)

References 26 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, glucocorticoids, antibiotics, bronchodilators and immunosuppressive agents are commonly used to treat acute radiation-induced lung injury. However, these strategies have suboptimal effect with side effects that may adversely affect the quality of patients' life (3,4).…”

Section: Introductionmentioning

confidence: 99%

Ophiopogon japonicus inhibits radiation-induced pulmonary inflammation in mice

Yao

Wang

et al. 2019

Ann. Transl. Med

View full text Add to dashboard Cite

Background: Radiation-induced lung injury, including the acute pulmonary inflammation and chronic pulmonary fibrosis remains the major complication of thoracic radiotherapy. Methods:In this study, we assessed the effects of Ophiopogon japonicus (O. japonicas) in inhibiting the radiation-induced pulmonary inflammation through an acute lung injury mouse model using C57BL/6 mice that received 18 Gy irradiation to the thoracic region. Starting at 4 days before radiation, mice were treated with O. japonicus or dexamethasone combined with cephalexin or vehicle daily for 14 days.Results: Exposure to radiation resulted in pulmonary inflammation in mice, but treatment with O. japonicus or dexamethasone-cephalexin could both significantly reduce radiation-induced pulmonary inflammation through inhibition of IL-6, TNF-α, TGF-β1, hydroxyproline, MDA, MMP-2 and TIMP-2 in plasma or lung tissue. In addition, through analyzing tissue damage, cytokines and inflammation-related protein at 12 weeks after irradiation, we found that the protective effect of O. japonicus was more enduring than dexamethasone-cephalexin.Conclusions: As radiation-induced lung injury is a major obstacle in thoracic radiotherapies and seriously affect the quality of patients' life. Application of O. japonicus may be a novel strategy to manage radiationinduced pulmonary inflammation.

show abstract

Section: Introductionmentioning

confidence: 99%

Ophiopogon japonicus inhibits radiation-induced pulmonary inflammation in mice

Yao

Wang

et al. 2019

Ann. Transl. Med

View full text Add to dashboard Cite

show abstract

“…Thus, it is an urgent issue to seek novel drugs for RIPI without serious side effects. CMs have a very long history of curing patients with lung diseases, in which some effective medicines may be found for the prevention and treatment of RIPI (Deng et al, 2017). In this review, we retrieved the most recent publications in the last 10 years, from 2007 to 2017, in different online databases to provide comprehensive insight into the efficacy of CMs on RIPI.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, type 1 helper T cells (Th1 cells) may affect RIPI by secreting IL-4 and IL-13, while type 2 helper T cells (Th2 cells) induce collagen synthesis for tissue remodeling and fibrosis (Huang et al, 2017). To date, the treatment strategies for RIPI are mainly based on glucocorticoids, angiotensin-converting enzyme inhibitors (ACEIs), and pentoxyphylline (Deng et al, 2017). Thus, a comprehensive review of the effects of CMs on RIPI may help discover the most effective CMs.…”

Section: Introductionmentioning

confidence: 99%

Chinese Medicines for Preventing and Treating Radiation-Induced Pulmonary Injury: Still a Long Way to Go

Ding

Liu

et al. 2019

Front. Pharmacol.

View full text Add to dashboard Cite

Thoracic radiotherapy is a mainstay of the treatment for lung, esophageal, and breast cancers. Radiation-induced pulmonary injury (RIPI) is a common side effect of thoracic radiotherapy, which may limit the radiotherapy dose and compromise the treatment results. However, the current strategies for RIPI are not satisfactory and may induce other side effects. Chinese medicines (CMs) have been used for more than a thousand years to treat a wide range of diseases, including lung disorders. In this review, we screened the literature from 2007 to 2017 in different online databases, including China National Knowledge Infrastructure (CNKI), Chongqing VIP, Wanfang, and PubMed; summarized the effectiveness of CMs in preventing and treating RIPI; explored the most frequently used drugs; and aimed to provide insights into potential CMs for RIPI. Altogether, CMs attenuated the risk of RIPI with an occurrence rate of 11.37% vs. 27.78% (P < 0.001) compared with the control groups. We also found that CMs (alone and combined with Western medical treatment) for treating RIPI exerted a higher efficacy rate than that of the control groups (78.33% vs. 28.09%, P < 0.001). In the screened literature, 38 CMs were used for the prevention and treatment of RIPI. The top five most frequently used CMs were Astragali Radix (with a frequency of 8.47%), Ophiopogonis Radix (with a frequency of 6.78%), Glycyrrhizae Radix et Rhizome (with a frequency of 5.08%), Paeoniae Radix Rubra (with a frequency of 5.08%), and Prunellae Spica (with a frequency of 5.08%). However, further high-quality investigations in CM source, pharmacological effects and underlying mechanisms, toxicological aspects, and ethical issues are warranted. Taken together, CMs might have a potential role in RIPI prevention and treatment and still have a long way to investigate.

show abstract

“…for the treatment of gastric, liver, and non-small cell lung carcinomas (24) and has also been observed to alleviate the toxicity of radiochemotherapy (25). Treatment regimens include 12-30 mL intravenous injection daily for 4-8 weeks and provided concurrently in patients getting radiotherapy (20,22,23).…”

mentioning

confidence: 99%

Evaluation of the Protective Effect of Compound Kushen Injection Against Radiation- induced Pneumonitis in Mice

Xu,

Chakraborty,

Wei

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Radiation-induced lung injury (RILI) via inflammation is a common adverse effect of thoracic radiation that negatively impacts patient quality of life and survival. Compound kushen injection (CKI), a botanical drug treatment, was examined for its ability to reduce RILI, and inflammatory responses and improve survival in mice exposed total lung irradiation (TLI). CKI’s specific mechanisms of action were also evaluated. Methods C3H mice underwent TLI and were treated with CKI (2, 4, or 8 mL/kg) intraperitoneally once a day for 8 weeks. The effects of CKI on survival were estimated by Kaplan-Meier survival analysis and compared by log-rank test. RILI damage was evaluated by histopathology and micro-computed tomography (CT). Inflammatory cytokines and cyclooxygenase metabolites were examined by IHC staining, western blot, and ELISA. Results Pre-irradiation treatment with 4 or 8 mL/kg CKI starting 2 weeks before TLI or concurrent treatment with 8 mL/kg CKI were associated with a significantly longer survival compared with TLI vehicle-treated group (P < 0.05). Micro-CT images evaluations showed that concurrent treatment with 8 mL/kg CKI was associated with significantly lower incidence of RILI (P < 0.05). Histological evaluations revealed that concurrent TLI treatment of CKI (4 and 8 mL/kg) significantly reduced lung inflammation (p < 0.05). Mechanistic investigation showed that at 72 hours after radiation, TLI plus vehicle mice had significantly elevated serum IL6, IL17A, and TGF-β levels compared with non-irradiated, age-matched normal mice; in contrast, levels of these cytokines in mice that received TLI plus CKI treatment were lower than those in the TLI plus vehicle-treated mice (P < 0.05) and similar to the nonirradiated mice. IHC staining showed that the CKI treatment led to a reduction of TGF-β positive cells in the lung tissues of TLI mice (P < 0.01). The concurrent CKI with TLI treatment group had a significant reduction in COX-2 activity and COX-2 metabolites compared with the TLI vehicle-treated group (P < 0.05). Conclusions These data suggest that CKI treatment was associated with reduced radiation-induced inflammation in lung tissues, reduced RILI, and improved survival. Further investigation of CKI in human clinical trials as a potential radioprotector against RILI to improve patients’ quality of life and survival is warranted.

show abstract

Chinese Herbal Extractions for Relieving Radiation Induced Lung Injury: A Systematic Review and Meta‐Analysis

Cited by 6 publications

References 26 publications

Ophiopogon japonicus inhibits radiation-induced pulmonary inflammation in mice

Ophiopogon japonicus inhibits radiation-induced pulmonary inflammation in mice

Chinese Medicines for Preventing and Treating Radiation-Induced Pulmonary Injury: Still a Long Way to Go

Evaluation of the Protective Effect of Compound Kushen Injection Against Radiation- induced Pneumonitis in Mice

Contact Info

Product

Resources

About